Ifosfamide
Ifex, Ifex/mesnex, Ifosfamide, Ifosfamide/mesna (ifosfamide) is a small molecule pharmaceutical. Ifosfamide was first approved as Ifex on 1988-12-30. It is used to treat b-cell chronic lymphocytic leukemia, breast neoplasms, hodgkin disease, lung neoplasms, and non-hodgkin lymphoma amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Ifosfamide (discontinued: Ifosfamide)
CombinationsIfex/mesnex (discontinued: Ifex/mesnex, Ifosfamide/mesna)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ifex | New Drug Application | 2024-12-02 |
| ifosfamide | New Drug Application | 2024-12-02 |
Indications
FDA
EMA
Show 3 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9208 | Injection, ifosfamide, 1 gram |
Clinical
Clinical Trials
532 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 40 | 119 | 36 | 8 | 7 | 190 |
| Sarcoma | D012509 | — | — | 21 | 72 | 37 | 3 | 18 | 139 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 15 | 40 | 17 | 3 | 1 | 65 |
| B-cell lymphoma | D016393 | — | — | 19 | 36 | 9 | 1 | 2 | 56 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 18 | 33 | 6 | 1 | 2 | 52 |
| Germ cell and embryonal neoplasms | D009373 | — | — | 8 | 30 | 8 | 1 | 2 | 41 |
| Leukemia | D007938 | — | C95 | 7 | 17 | 12 | 3 | 2 | 39 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 4 | 10 | 14 | 5 | 2 | 33 |
| T-cell lymphoma | D016399 | — | — | 6 | 17 | 2 | 4 | — | 27 |
| T-cell lymphoma peripheral | D016411 | — | — | 6 | 13 | 2 | 4 | — | 23 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 26 | 25 | 10 | — | 3 | 53 |
| Osteosarcoma | D012516 | — | — | 12 | 26 | 8 | — | 7 | 45 |
| Hodgkin disease | D006689 | — | C81 | 9 | 21 | 9 | — | 1 | 33 |
| Recurrence | D012008 | — | — | 9 | 18 | 3 | — | 1 | 27 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 3 | 11 | 7 | — | 5 | 25 |
| Rhabdomyosarcoma | D012208 | — | — | 3 | 14 | 5 | — | 2 | 22 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 8 | 15 | 5 | — | — | 22 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 7 | 9 | 4 | — | 2 | 20 |
| Lung neoplasms | D008175 | — | C34.90 | 3 | 7 | 7 | — | 2 | 17 |
| Carcinoma | D002277 | — | C80.0 | 1 | 11 | 2 | — | 1 | 15 |
Show 72 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 8 | — | — | — | 9 |
| Extranodal nk-t-cell lymphoma | D054391 | — | C86.0 | 2 | 7 | — | — | — | 8 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | 6 | — | — | — | 6 |
| Transitional cell carcinoma | D002295 | — | — | 2 | 5 | — | — | — | 6 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 4 | 5 | — | — | — | 6 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | 3 | — | — | 2 | 5 |
| Wilms tumor | D009396 | EFO_0000212 | — | 2 | 2 | — | — | 1 | 5 |
| Penile neoplasms | D010412 | — | C60 | — | 5 | — | — | — | 5 |
| Myeloid leukemia | D007951 | — | C92 | 2 | 2 | — | — | — | 4 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | 3 | — | — | — | 4 |
Show 75 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinoblastoma | D012175 | — | — | 1 | — | — | — | 1 | 2 |
| Rhabdoid tumor | D018335 | — | — | 1 | — | — | — | 1 | 2 |
| Hepatoblastoma | D018197 | — | C22.2 | 1 | — | — | — | 1 | 2 |
| Intestinal diseases | D007410 | — | K63.9 | 1 | — | — | — | — | 1 |
| Thymoma | D013945 | — | — | 1 | — | — | — | — | 1 |
| Neuroepithelial neoplasms | D018302 | — | — | 1 | — | — | — | — | 1 |
| Hairy cell leukemia | D007943 | — | C91.4 | 1 | — | — | — | — | 1 |
| Intraocular lymphoma | D064090 | — | — | 1 | — | — | — | — | 1 |
| Large granular lymphocytic leukemia | D054066 | — | — | 1 | — | — | — | — | 1 |
| Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pituitary diseases | D010900 | — | E23.7 | — | — | — | — | 2 | 2 |
| Medulloblastoma | D008527 | — | — | — | — | — | — | 1 | 1 |
| Retinal neoplasms | D019572 | — | C69.2 | — | — | — | — | 1 | 1 |
| Disease | D004194 | EFO_0000408 | R69 | — | — | — | — | 1 | 1 |
| Thyroid diseases | D013959 | — | E00-E07 | — | — | — | — | 1 | 1 |
| Pituitary neoplasms | D010911 | — | — | — | — | — | — | 1 | 1 |
| Sex cord-gonadal stromal tumors | D018312 | EFO_1000052 | — | — | — | — | — | 1 | 1 |
| Pinealoma | D010871 | — | — | — | — | — | — | 1 | 1 |
| Sertoli-leydig cell tumor | D018310 | — | — | — | — | — | — | 1 | 1 |
| Nodular goiter | D006044 | EFO_1001062 | — | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ifosfamide |
| INN | ifosfamide |
| Description | Ifosfamide is the simplest member of the class of ifosfamides that is 1,3,2-oxazaphosphinan-2-amine 2-oxide substituted by 2-chloroethyl groups on both the nitrogen atoms respectively. It is a nitrogen mustard alkylating agent used in the treatment of advanced breast cancer. It has a role as an antineoplastic agent, an immunosuppressive agent, an alkylating agent, an environmental contaminant and a xenobiotic. |
| Classification | Small molecule |
| Drug class | phosphoro-derivatives; isophosphoramide mustard derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=P1(NCCCl)OCCCN1CCCl |
Identifiers
| PDB | — |
| CAS-ID | 3778-73-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1024 |
| ChEBI ID | 5864 |
| PubChem CID | 3690 |
| DrugBank | DB01181 |
| UNII ID | UM20QQM95Y (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 20,431 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ifex, Ifosfamide
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
19,614 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use